China Surpassed the U.S. in R&D Spending in 2024: Here Are the Numbers That Matter

For the first time on record, China's total research and development (R&D) spending surpassed that of the United States in 2024. Multiple authoritative sources — including Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Organisation for Economic Co-operation and Development (OECD), and the U.S. National Science Board (NSB) — now agree that the long-anticipated crossover has occurred. The milestone carries significant implications for global science, technology competition, and future innovation capacity, though the U.S. retains advantages in several quality-based metrics.

What the 2024 R&D Spending Data Show

Japan's "Science and Technology Indicators 2026" report, released on August 7, 2026, by MEXT, found that China's combined business and university R&D investment reached ¥97.1 trillion ($615 billion at exchange rates) in 2024, a 13.1% year-on-year increase. The United States spent ¥95.3 trillion, up 6.7%. Japan ranked third at ¥22.1 trillion .

These figures are corroborated by OECD data using purchasing power parity (PPP) adjustments, the standard method for international comparability. Under PPP:

• China: $1.028–$1.03 trillion in gross domestic R&D expenditures (GERD) in 2024
• United States: $1.009–$1.01 trillion over the same period
• Global total R&D spending: $3.48 trillion

Together, China (30%) and the United States (29%) account for 59% of global R&D performance .

A critical methodological note: China's lead is most pronounced under PPP adjustments, which account for differences in cost structures between economies. On a nominal exchange-rate basis, the U.S. still leads. The OECD and NSB use PPP as the standard for international comparability, making it the measure cited by most official analyses .

Key Drivers Behind China's Overtaking

Sustained double-digit growth. China's R&D spending grew at 13.1% in 2024, nearly double the U.S. growth rate of 6.7%. For at least a decade, China has increased overall research spending at nearly 10% annually, far eclipsing the U.S. rate of increase .

Corporate investment is the engine. The MEXT report specifically tracks "total R&D expenditures by companies and universities," and enterprise investment is cited as the primary driver. China's corporate R&D spending grew 13% to ¥75.4 trillion, with computer, electronics, and optical products leading the surge .

Industrial policy and talent recruitment. The OECD and NSB attribute China's rise to sustained government investment, industrial policy targets such as "Made in China 2025," and aggressive recruitment of scientific talent .

Sectoral headway. Chinese firms are already outpacing U.S. firms' R&D investment intensity in four of nine advanced technology sectors studied by the Information Technology and Innovation Foundation. Excluding software and biopharmaceuticals, Chinese firms' wage-adjusted R&D across seven advanced industries now exceeds U.S. firms' R&D by 6% .

Broader Implications

Quality versus quantity. While China leads in total spending, U.S. science retains clear advantages in research quality, high-impact publications, basic research share, and Nobel-level output. The NSB notes that U.S. strengths "persist" even as China's momentum grows .

The lab-to-market gap closes. China is narrowing the traditional gap between research output and commercial application, long considered a weakness of its innovation system .

U.S. policy response. Over 3,300 U.S. scientists have urged Congress to increase federal R&D funding to maintain competitiveness. The OECD and NSB findings have reignited debates about the CHIPS and Science Act and broader innovation policy .

Strategic technology leadership. China now leads in key indicators such as AI patent filings (82,708 international patent families in 2024, ranking first globally) and quantum information technology patents (4,319 cases, compared to 812 for the U.S.) .

Caveats and Nuance

China's R&D intensity (R&D as a percentage of GDP) still trails the U.S. China reported R&D intensity of 2.69% of GDP in 2024 , below the U.S. figure. The U.S. continues to lead in nominal, non-PPP-adjusted spending as well as in basic research funding and high-impact scientific output .

The Japan report's finding is a significant symbolic and quantitative milestone, but as the NSB and others emphasize, it does not signal a complete reversal of scientific leadership. Total spending volume is one dimension of a complex picture that includes research quality, talent density, and institutional strengths that remain in the U.S. system.